A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 35

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

373

HTML

2994

Figures (1-1)

151

Tables (1-3)

154

Sum=3672

Publishing Process of This Article

Item

Count

Browse

834

Download

751

Sum=1585

Sep 21, 2013 (publication date) through Apr 27, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Sep 21, 2013; 19(35): 5910-5916
Published online Sep 21, 2013. doi: 10.3748/wjg.v19.i35.5910

Figure 1 Kaplan-Meier analysis of progression-free survival (A) and overall survival (B) in the study population

Citation: He YF, Ji CS, Hu B, Fan PS, Hu CL, Jiang FS, Chen J, Zhu L, Yao YW, Wang W. A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World J Gastroenterol 2013; 19(35): 5910-5916
URL: https://www.wjgnet.com/1007-9327/full/v19/i35/5910.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i35.5910